Salim Syed
Stock Analyst at Mizuho
(2.31)
# 2,733
Out of 5,045 analysts
75
Total ratings
43.33%
Success rate
0.39%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Salim Syed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NKTX Nkarta | Maintains: Outperform | $16 → $14 | $2.09 | +569.86% | 8 | Jun 10, 2025 | |
| CYTK Cytokinetics | Maintains: Outperform | $103 → $84 | $61.99 | +35.51% | 7 | May 29, 2025 | |
| BIIB Biogen | Maintains: Outperform | $207 → $169 | $147.86 | +14.30% | 16 | May 7, 2025 | |
| AMGN Amgen | Maintains: Neutral | $235 → $280 | $291.77 | -4.03% | 8 | May 7, 2025 | |
| GILD Gilead Sciences | Maintains: Outperform | $100 → $117 | $118.50 | -1.27% | 7 | May 5, 2025 | |
| WVE Wave Life Sciences | Maintains: Outperform | $19 → $22 | $8.26 | +166.34% | 5 | Nov 21, 2024 | |
| PCVX Vaxcyte | Maintains: Outperform | $113 → $163 | $43.52 | +274.54% | 3 | Sep 10, 2024 | |
| ATRA Atara Biotherapeutics | Upgrades: Outperform | $25 → $18 | $14.06 | +28.02% | 4 | Aug 16, 2024 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $34 | $22.65 | +50.11% | 1 | Apr 9, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Buy | $82 → $99 | $62.56 | +58.25% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $53 | $66.62 | -20.44% | 7 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $21 | $1.73 | +1,113.87% | 5 | Nov 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $168 → $36 | $30.99 | +16.17% | 1 | Nov 16, 2022 |
Nkarta
Jun 10, 2025
Maintains: Outperform
Price Target: $16 → $14
Current: $2.09
Upside: +569.86%
Cytokinetics
May 29, 2025
Maintains: Outperform
Price Target: $103 → $84
Current: $61.99
Upside: +35.51%
Biogen
May 7, 2025
Maintains: Outperform
Price Target: $207 → $169
Current: $147.86
Upside: +14.30%
Amgen
May 7, 2025
Maintains: Neutral
Price Target: $235 → $280
Current: $291.77
Upside: -4.03%
Gilead Sciences
May 5, 2025
Maintains: Outperform
Price Target: $100 → $117
Current: $118.50
Upside: -1.27%
Wave Life Sciences
Nov 21, 2024
Maintains: Outperform
Price Target: $19 → $22
Current: $8.26
Upside: +166.34%
Vaxcyte
Sep 10, 2024
Maintains: Outperform
Price Target: $113 → $163
Current: $43.52
Upside: +274.54%
Atara Biotherapeutics
Aug 16, 2024
Upgrades: Outperform
Price Target: $25 → $18
Current: $14.06
Upside: +28.02%
Enliven Therapeutics
Apr 9, 2024
Initiates: Buy
Price Target: $34
Current: $22.65
Upside: +50.11%
CRISPR Therapeutics AG
Mar 6, 2024
Maintains: Buy
Price Target: $82 → $99
Current: $62.56
Upside: +58.25%
Mar 5, 2024
Maintains: Buy
Price Target: $60 → $53
Current: $66.62
Upside: -20.44%
Nov 16, 2022
Maintains: Buy
Price Target: $28 → $21
Current: $1.73
Upside: +1,113.87%
Nov 16, 2022
Maintains: Buy
Price Target: $168 → $36
Current: $30.99
Upside: +16.17%